Frontier Bio

About the offering

Frontier Bio is a revenue-generating biotech company engineering human tissues to address two major healthcare challenges: replacing animal testing in preclinical drug development and developing implantable tissue-engineered vascular grafts to address the organ shortage crisis. Based in Hayward, CA, the company has generated $5.5M in cumulative sales by selling lab-grown human tissue models to customers including Intuitive Surgical and Mayo Clinic. The company's CTO, Dr. Sam Pashneh-Tala, authored the seminal ~1,000-citation review paper on tissue-engineered blood vessels, and the advisory team includes Dr. George Church, Harvard Medical School genetics professor, National Academy of Sciences/Engineering member, and co-founder of Editas Medicine and Colossal Biosciences. The Wefunder campaign has raised $1,660,982 from 44+ investors, with $4.1M raised to date across all sources.The ProblemMedicine faces critical shortages of functional human tissue across three domains. In preclinical testing, pharmaceutical companies still rely heavily on animal models that are expensive, time-consuming, and fundamentally inaccurate—approximately 90% of drugs that pass animal studies fail in human clinical trials, representing billions of dollars in wasted R&D. Regulatory agencies including the FDA are now actively encouraging alternatives to animal testing, but better human-based tools are needed to make that transition practical.In vascular surgery, synthetic grafts remain the standard for procedures including dialysis access, coronary artery bypass, and peripheral artery bypass. These synthetic grafts do not biologically integrate with the body and fail at rates reaching 65% within two years in small-diameter vessel applications, leading to additional surgeries, higher costs, and worse patient outcomes. The alternative—harvesting the patient's own vein—prolongs surgery and causes donor-site injury.In organ transplantation, more than 100,000 people in the US wait for organ transplants, and according to the WHO, only 10% of global organ demand is met. Lifetime care costs can exceed $1M per patient, creating a $100B+ market opportunity with a shortage that continues to widen as demand outpaces supply.The SolutionFrontier Bio addresses these problems through two product lines built on a shared tissue engineering platform.For preclinical testing, the company creates lab-grown human tissue models engineered to reproduce biological functions of the brain, lungs, and blood vessels, providing a human-relevant platform for evaluating therapeutic safety and biological activity. These high-fidelity models serve as alternatives to animal studies and support evaluation of pharmaceutical drugs and novel cell therapies. Partners use these models to generate human-relevant data early in development.For clinical applications, the company is developing a regenerative vascular graft that combines the patient's own stem cells with a bioresorbable scaffold at the bedside. The graft is engineered to conduct blood flow immediately upon implantation, then over time the biodegradable scaffold is absorbed and replaced by living tissue, creating a durable vessel that integrates naturally and minimizes long-term foreign body rejection risk. Target applications include dialysis access (AV access) as the beachhead, with expansion planned into coronary artery bypass, peripheral artery bypass, and trauma repair.The long-term vision positions blood vessels as the foundational infrastructure for full organ engineering—developing functional vascular tissue now lays the groundwork for eventually engineering transplantable organs including pancreas, lung, kidney, liver, and heart.Business ModelFrontier Bio operates a revenue-first biotech model with near-term and long-term revenue streams. The current growth engine is human tissue sales and services: providing high-fidelity tissue models and bespoke R&D services to commercial partners, academic institutions, and government customers. High-value contracts range from $250K to $1.1M per engagement. The strategic sales approach focuses on executing successful pilot projects and transitioning them into broader, long-term research partnerships.The clinical vertical (in development) will focus on direct sales of tissue-engineered vascular grafts to hospitals and surgical centers. The beachhead application is dialysis vascular access, chosen for its critical clinical need, established reimbursement pathways, and defined regulatory framework. Expansion targets include trauma, coronary artery bypass, and peripheral artery disease bypass.TractionThe company has generated $5.5M in cumulative sales—exceptional for a preclinical-stage biotech. World-class customers and partners include Intuitive Surgical and Mayo Clinic. Individual contracts range from $250K to $1.1M. The company is VC-backed, having raised $250K+ from venture firms. Total funding to date is $4.1M, with $1.6M committed in the current Wefunder round ($1,660,982 raised from 44+ investors). The featured investor is Rob Ness of Asymmetry, who invested $72,482 and specifically cited the company's capital efficiency and contracts with Intuitive Surgical and Mayo Clinic. The vascular graft program is advancing toward human trials with early FDA engagement to clarify the regulatory path. The company participates in established defense, manufacturing, and innovation ecosystems including MTEC, ARMI, StartX, Alchemist Accelerator, Brinc, and NSF SBIR Beat-the-Odds Bootcamp. The CTO's seminal review paper on tissue-engineered blood vessels has approximately 1,000 citations, establishing deep scientific authority.Market OpportunityThe human tissue models market (animal alternative) is estimated at approximately $2.1B globally and growing as regulatory agencies expand the use of human-based research tools. The vascular graft market serves hundreds of thousands of procedures annually, with small-diameter grafts representing a severely underserved segment where current synthetic options fail at rates up to 65% within two years. The regenerative medicine and lab-grown organ market represents a $100B+ opportunity based on unmet organ transplant demand, with only 10% of global organ need currently met and lifetime care costs exceeding $1M per patient. The lung transplant market alone involves significant costs and limited supply.TeamCEO Eric Bennett, MSc, is a serial entrepreneur and biomedical engineer who previously served as CTO at Aether, where he designed advanced, low-cost 3D bioprinters. His deep-tech expertise spans DNA assembly, microfluidics, biofabrication, optogenetics, and brain-computer interfaces. CTO Dr. Sam Pashneh-Tala, PhD, is a recognized expert in tissue-engineered blood vessels who authored the field's seminal review paper (~1,000 citations). He completed his PhD and fellowship in the field and previously ran an advanced medical device and tissue engineering consultancy. Advisor Dr. George M. Church, PhD, is a Harvard Medical School genetics professor and synthetic biology pioneer, member of both the National Academy of Sciences and National Academy of Engineering, and co-founder of multiple biotech companies including Editas Medicine and Colossal Biosciences.

FAQ